山东鲁抗医药股份有限公司 关于“提质增效重回报”行动方案的公告

Core Viewpoint - The company has developed an action plan titled "Enhancing Quality, Increasing Efficiency, and Returning to Shareholders" to improve operational quality and governance in response to regulatory requirements and its own strategic goals [1][8]. Group 1: Business Focus and Quality Improvement - The company is a state-controlled comprehensive pharmaceutical enterprise engaged in the research, production, and sales of pharmaceutical and biological manufacturing products, with a mission to develop ecological medicine and serve human health [1]. - Future strategies include optimizing business structure and enhancing operational efficiency, focusing on product innovation and establishing a high-quality development system [2]. Group 2: Innovation and Product Line Expansion - The company adheres to an "innovation-driven development" strategy, maintaining R&D investment at over 6% of revenue during the 14th Five-Year Plan period, and has achieved breakthroughs in innovative drugs and biological manufacturing [2][3]. - The product structure is continuously optimized, with competitive advantages in anti-infection, diabetes, and cardiovascular drugs, and a growing pipeline of specialty products [2]. Group 3: Governance and Compliance - The company is committed to improving its governance structure in accordance with relevant laws and regulations, ensuring transparency and effective checks and balances [3][4]. - It has revised its articles of association and internal control systems to enhance operational standardization and compliance [3]. Group 4: Long-term Return Mechanism - The company emphasizes investor returns, with cash dividends exceeding 30% of net profit attributable to ordinary shareholders from 2021 to 2024, and has incorporated a cash dividend policy into its articles of association [5]. - The company aims to enhance its operational quality to increase investment value and fulfill its commitment to shareholder returns [5]. Group 5: Information Disclosure and Investor Relations - The company adheres to strict information disclosure regulations, focusing on transparency and the quality of disclosed information to ensure all shareholders receive timely updates [6]. - It plans to enhance investor relations management through diversified communication channels and actively seek investor feedback [6]. Group 6: Management of Key Personnel - The company prioritizes the responsibilities of key stakeholders, including controlling shareholders and senior management, to safeguard the interests of minority shareholders [7]. - It implements a multi-level governance system to ensure compliance and risk management, while enhancing the performance evaluation and incentive mechanisms for senior management [7].